 |
Epirubicin taxotere |
|
Based on empirical drug limitations about 1015% of patients will develop congestive heart failure CHF ; with a mortality of 50% within 2 years on digitalodiuretic therapy alone. To avoid CHF there is a consensus recommendation that cardiac function should be monitored in close connection with anthracycline administration. As no prospective studies in a larger series have been performed, these recommendations are based on retrospective data on small numbers of patients. Patients and methods: In a prospective, blinded observational study 120 patients with advanced breast cancer were followed before, during, and a median 3 years after treatment with epirubicin. They had 604 serial radionuclide measurements of left ventricular ejection fraction LVEF ; that were stored without calculations except in patients who developed a well-defined CHF. Results: Anthracycline cardiotoxicity was closely correlated with the cumulative dose, with a great variability in individual susceptibility and a dramatic increase with advancing age. With a delayed onset of 3 months or more, epirubicin induced a threatening, slowly progressive deterioration of cardiac function continuing years after treatment. An actuarial estimation of 59% of the patients experienced a 25% relative reduction in LVEF 3 years after 8501000 mg m2 of epirubicin and 20% had deteriorated into a CHF. The patients did not spontaneously regain cardiac function whereas continued therapy with a circadian angiotensin-converting enzyme inhibitor for more than 3 months caused a remarkably potent and long-lasting recovery. Conclusions: Due to the displaced cardiotoxic manifestation, functional monitoring in close connection with anthracycline administration appears to be a poorly effective method while later monitoring is essential. Current monitoring recommendations should therefore be revised. Key words: angiotensin-converting enzyme inhibition, anthracyclines, cardiotoxicity, free radical toxicity, radionuclide ejection fraction, recurrent breast cancer.
Myelosuppression is the major dose limiting toxicity and may be severe and even life threatening. Hyperuricemia during periods of active cell lysis, which is caused by cytotoxic chemotherapy of highly proliferative tumours of massive burden e.g., some leukemias and lymphomas ; , can be minimized with allopurinol and hydration. In hospitalized patients the urine may be alkalinized, by addition of sodium bicarbonate to the IV fluids, if tumour lysis is expected. Epirubicin is associated with cardiac toxicity. Transient ECG changes and arrhythmias occurring up to 2 weeks after a dose are not considered indications for discontinuation of therapy. Serious, irreversible cardiomyopathy with delayed congestive heart failure often unresponsive to therapy may be encountered as 2 the cumulative dose approaches 1000 mg m . Cardiac monitoring is advised when cumulative dose exceeds 2 650 mg m . The risk of cardiomyopathy is increased at a lower cumulative dose when the patient has received prior treatment with anthracycline anthracendiones mitomycin C, radiation therapy or has pre-existing cardiac risk factors. The onset of cardiotoxicity may be late and occur after treatment has been discontinued, and may be resistant to medical treatment. Dexrazoxane may be use as a cardioprotectant in patients with advanced or metastatic cancer who are at risk of developing cardiotoxicity when receiving chemotherapy containing epirubicin. See CCO Practice Guidelines "Use of Dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer" If used in children, the cumulative tolerated dose is lower than for adults. Erythematous streaking a histamine release phenomenon ; along the vein proximal to the site of injection has been reported, and must be differentiated from an extravasation event. This 'epirubicin flare' reaction usually subsides within 30 minutes. The injection may be continued, more slowly in the same site or may be changed to another site. Diphenhydramine 25 mg or hydrocortisone 100 mg, by slow IV push over 5 minutes into the IV line may hasten clearing of the reaction. The tissue necrosis that happens with extravasation may happen days to weeks after the treatment. Patients must be observed for delayed reactions and prior injection sites carefully inspected. Epirubicin has the potential to enhance radiation injury to tissues. While often called radiation recall reactions, the timing of the radiation may be before, concurrent with or even after the administration of the epirubicin. Recurrent injury to a previously radiated site may occur weeks to months following radiation.
Epirubicin dogs
Side Lateral Raises: Hold weights at sides, palms turned in. Slowly raise arms to shoulder height and return to sides. Bicep Twists: Hold weights at sides, slightly bending elbows, and palms facing inward. Lifting weights to elbow height, slowly twist weights away from sides so palms face the ceiling. Return to starting position. Focus on contracting the biceps as you lift the weight. Seated Oblique and Abdominal Crunch: Sit with feet shoulder width apart. While bending your right knee and raising leg off the floor, crunch right elbow toward the knee. Repeat on left side. Focus on contracting your abdominal and oblique muscles. You should aim for approximately 20 to 30 repetitions, depending on your comfort level.
The frequency of TxCAD for all groups was evaluated by use of two end points. First, the percentage of animals with "significant TxCAD, " defined as intimal thickening afflicting 5% of vessels within a section, was determined for each group. Second, the average percentage of vessels with any TxCAD was calculated for each group of animals Table 3 ; . Significant TxCAD was found predominantly in allograft diabetic animals [Allo D F], 82% ; . In contrast, no TxCAD was seen in nondiabetic allografts [Allo D F], P 0.0001 ; . Significant TxCAD was present in 29% of diabetic isografts Iso D F however, compared with the diabetic allografts, both the frequency 29% versus 82%, P 0.002 ; and severity grade 1.1 0.4 versus 3.2 0.5, P 0.03 ; of TxCAD were lower in the diabetic isografts. The frequency of significant TxCAD in allografts from diabetic recipient animals was 89% in the nonfructose-fed group and 75% in the fructose-fed group. The average percentage of affected vessels in the nonfructose-fed diabetic versus fructose-fed group was 73% versus 60%, respectively. Fructose feeding did not significantly affect the severity or frequency of TxCAD in any of the groups studied, although there was a distinct trend toward less TxCAD in fructose-fed animals. Figure 3 shows the spectrum of TxCAD seen in this study, ranging from mild intimal proliferation with only partial involvement of the circumference of the vessel grade 1 ; to severe luminal compromise grade 5 ; . Figure 4 compares a normal coronary artery from a transplanted heart of a nondiabetic animal with a coronary.
On the other hand, in 2001, we noted a first inversion in the trend, with approximately a 30% decrease in IC cases: IC were only 15, with a standardized incidence of 9.6 in 100 000; this rate then returned to lower levels compared to the average data for the pre-screening decade, while the new early diagnoses relating to in CIS were 82. Mortality has shown a progressive decrease, going from 3.9 in 100 000 in the 1988 97 period to 3.0 in 100 000 in the past 4-year period. On the basis of these results, we may conclude that the 3-yearly screening policy is considered safe and that it is important for the screening to continue. L8 WEEKLY HIGH-DOSE CALCITRIOL, DOCETAXEL AND EPIRUBICIN IN METASTATIC HORMONE-RESISTANT PROSTATIC CANCER Roberto Petrioli1, Marianna Sabatino1, Stefania Marsili1, Loretta Paolelli1, Angela Sciandivasci1, Alessandra Pascucci1, Domenico Ciliberto1, Mirco Bindi1, Pierpaolo Correale1, Giovanni De Rubertis2, Gabriele Barbanti2, Antonio Manganelli2, Francesco Salvestrini3, Guido Francini1 1 Department of Human Pathology and Oncology; 2Department of Urology; 3Clinical Urology, University of Siena, Siena, Italy The aim of this study was to evaluate the safety and efficacy of a new regimen that combines high-dose calcitriol with docetaxel Taxotere ; and epirubicin administered on a weekly schedule to patients with hormone-resistant prostatic cancer HRPC ; . The patients were admitted to the chemotherapy protocol provided that they met at least one of the following criteria: an increase in PSA level of 50% in comparison with baseline on two successive occasions separated by at least 2 weeks; new metastatic lesions revealed by a bone scan; an increase of more than 25% in a bidimensionally measurable tumor mass. Treatment consisted of oral calcitriol at escalation doses from 8 to 32 mg ; on days 1 3, followed by docetaxel 30 mg m2 i.v. and epirubicin 30 mg m2 i.v. on day 2, repeated weekly for 6 weeks of an 8-week cycle. PSA response was the primary end point, which was defined as a 50% reduction in PSA level confirmed 4 weeks later. Secondary end points were palliative response, defined as reduction in pain intensity, the duration of biochemical and palliative response, and survival. Twenty-three patients had been enrolled; all of the patients were assessable for toxicity, 19 were assessable for response. The treatment was well tolerated: grade 3 neutropenia was observed in 17% of the patients, grade 3 anemia in 13%, and grade 3 thrombocytopenia in 8%. None of the patients developed grade 4 toxicity or congestive heart failure. Fifteen of 19 assessable patients 79% ; achieved a PSA response. Pain was reduced in 14 of patients 82% ; who were symptomatic at baseline. These preliminary results indicate that the combination of weekly oral high-dose calcitriol with docetaxel and epirubicin is a welltolerated regimen with high activity in metastatic HRPC.
Epirubicin sicor
| Adriamycin epirubicinDrug analyses were performed by a Waters LC Module I plus equipped with a WISP 416 autosampler, a variable wavelength UV detector and a model 474 scanning fluorescence spectrophotometer Waters ; . Human blank plasma was used as calibrant matrix and spiked with drugs to generate calibration curves. The relationship between spiked drug concentrations and the UV absorption or fluorescence was linear r2 0.995, linear regression analysis, weighting 1 X2 ; over the analytical range from 0.05 to 150 g ml of gemcitabine and dFdU, from 0.05 to 50 mol l for paclitaxel, and from 0.005 to 50 g for epirubicin and epirubicinol. Limits of quantitation corresponded to the lower limit of calibration curves. The inaccuracy overall percentage bias ; of the assays were within the range of 2.28.1% for gemcitabine and dFdU, 1.57.9% for paclitaxel and 1.86.2% for epirubicin and epirubicinol. Both the intra-assay and interassay precision coefficients of variation ; were 8.2% for gemcitabine and dFdU, 6.5% for paclitaxel, and 9.7% for epirubicin and epirubicinol. Finally, the absolute recovery were in the range of 90105% for gemcitabine and dFdU, while for epirubicin epirubicinol and paclitaxel, recovery values of 61109% and 87109%, respectively, were found and eplerenone.
S.: Deoxyribonucleic acid synthesis in cultured human cells and its bearing on the concepts of endoreduplication and polyploidy. Nature London ; 208: 242, 1965
2003: cisplatin and epirubicin 40 mg m2 day 1, gemcitabine 600 mg m2 day 1 and 8, 5-fluorouracil FU ; 200 mg m2 day continuous infusion ; or dose-intense PEFG Dell'Oro S, Ann Oncol 2004; since July 2003: cisplatin and epirubicin 30 mg m2, gemcitabine 800 mg m2 every 14 days; 5-FU 200 mg m2 day continuous infusion ; until PD or a maximum of 6 cycles. Tumor was assessed every 2 months. Results: Since January 2000, 45 pts median age 60; range 4073; median KPS 80; M: F 24: 21 ; received 69 cycles of classical PEFG 18 pts ; or 88 cycles of dose-intense 27 pts ; PEFG as salvage treatment. 35 pts 78% ; had metastatic disease; 10 pts 12% ; local relapse or progression; 25 pts 55% ; had a CA 199 value 5 times the upper limit of laboratory normal; 22 pts 49% ; had prior surgery; 20 pts 45% ; had a previous progression-free survival PFS ; 6 months. Previous treatment was single agent gemcitabine N 17 ; , gemcitabine-based chemotherapy N 4 ; , or PEFG regimen N 24 ; . Chemotherapy is ongoing in 3 pts and 2 pts are not yet assessable for response. 7 pts 17% ; completed 6 cycles of chemotherapy; 35 pts interrupted CHT due to radiological 22 pts ; or clinical 3 ; PD, toxicity 2 ; , patient's refusal 2 ; , physician's decision 6 ; . Grade 2 toxicity consisted of neutropenia in 26 pts 58% ; 66% classical PEFG vs. 52% dose-intense PEFG ; , thrombocytopenia in 10 22% ; 28% vs. 7% ; , anemia in 9 20% ; 22% vs. 18% ; , fatigue and stomatitis in 4 8% ; , vomiting, diarrhea and hand-foot syndrome in 2 4% ; . classical PEFG + 3 doseintense PEFG ; pts 20% ; had partial response, 15 7 classical PEFG + 8 dose-intense PEFG ; 38% ; stable disease. Median and 1-yr survival OS ; was 7.5 months 8 vs. 6 months ; and 18% 17% vs 19% ; . Median and 6-months PFS was 3.9 months 3.8 vs. 3.9 months ; and 33% vs. 33% ; . Previous surgery or chemotherapy regimen, PFS or 6 months ; , CA 19-9 value or 5 U ; and disease site did not predict OS. Conclusions: PEFG regimen in gemcitabine pre-treated advanced PC was feasible, had an acceptable toxicity profile and interesting activity and may constitute a treatment opportunity in this setting and epogen.
Epirubicin msds
| The treatment for locally advanced breast cancer starts with chemotherapy given before surgery. The chemotherapy regimen should contain an anthracycline doxorubicin or epirubicin ; or a taxane paclitaxel or docetaxel.
Fig. 4. Stereo view of the retinal-binding pocket in the putative mutant octopus rhodopsin superimposed on the retinal pocket of bacteriorhodopsin. Backbones of the octR and bR as well as residue numbers are in green and cyan, respectivevly. Side chains are CPK-colored and epoprostenol.
Selected fluoroquinolones have excellent in-vitro activity against Neisseria gonorrhoeae, including strains with plasmid-mediated penicillin resistance, plasmid-mediated tetracycline resistance and chromosomally mediated resistance to penicillin and or tetracycline. These agents have been demonstrated to be highly effective in curing uncomplicated gonorrhoea. Recently, however, we have found the emergence of clinical strains of N. gonorrhoeae with decreased susceptibility to fluoroquinolones and have observed fluoroquinolone treatment failures in gonorrhoea. Several mechanisms of quinolone resistance have been identified and characterized in N. gonorrhoeae strains with decreased susceptibility to quinolones. In laboratory mutant strains, alterations of the GyrA subunit of DNA gyrase play a primary role in conferring quinolone resistance in N. gonorrhoeae.1 Alterations in the ParC subunit of DNA topoisomerase IV are responsible for an increase in resistance to fluoroquinolones.1 In clinical isolates of N. gonorrhoeae, we have demonstrated that alterations in.
6 and days 1 and 2 Tables 1 and 2 ; . However, was a significant increase in 6-mm WD mean SD, 27 42 m; p O.O5 ; . In the placebo and eprosartan.
1. Jantunen IT, Kataja VV, Muhonen TT et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996; 37: 502-4. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet. 1992; 340: 1107. Letter. 3. Hesketh P, Navari R, Grote T at al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol. 1996; 14: 2242-9. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997; 15: 2966-73. Baltzer L, Kris MG, Hinkley L at al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron OND ; and dolasetron mesylate DM ; : a possible drug class effect without sequelae? Proc Soc Clin Oncol. 1994; 13: 433. Abstract 1489. 6. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996; 32A 5 ; : 807-13. 7. Roila et al. Proc MASCC. 2000. 8. Roila F, Verena De Angelis S, Palazzo F et al. Antiemetic prescriptions and effectiveness in cancer patients submitted to chemotherapy of intermediate emetogenic potential. Proc Soc Clin Oncol. 2001; 20. Abstract 1587. 9. Coates A, Abraham S, Kaye SB, et al. On the receiving end-- patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19: 203-8. Griffin AM, Buttow PN, Coates A et al. On the receiving end. V: Patients perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7: 189-95.
Doxorubicin vs epirubicin
S2. HORMONES AND RELATED SUBSTANCES ; The following substances and their releasing factors, are prohibited: 1. Erythropoietin EPO 2. Growth Hormone hGH ; , Insulin-like Growth Factors e.g. IGF-1 ; , Mechano Growth Factors MGFs 3. Gonadotrophins e.g. LH, hCG ; , prohibited in males only; 4. Insulins; 5. Corticotrophins and erbitux.
BRAND PRODUCTS REMOVED Generics remain COREG carvedilol tabs ; ELLENCE epirubicin inj ; FLOXIN OTIC ofloxacin otic soln ; NEORAL cyclosporine modified caps, oral soln ; NIPENT pentostatin for inj ; SANDIMMUNE cyclosporine caps, oral soln ; ALL VERSIONS, BRAND AND OR GENERIC, REMOVED AVANDAMET rosiglitazone metformin tabs ; AVANDIA rosiglitazone tabs ; carbachol ophth soln PRAMOSONE pramoxine 1% hydrocortisone acetate 2.5% crm, lotn, oint ; DISCONTINUED BRAND PRODUCTS REMOVED PANCRELIPASE amylase lipase protease caps, 20, 000 4000 25, 000 units ; SORIATANE acitretin caps ; [added SORIATANE CK KIT] DISCONTINUED GENERIC PRODUCTS REMOVED guaifenesin codeine liq, 300-10 mg 20 mL hydrocodone guaifenesin syrup, 2.5-200 5 mL, 5-100 5 mL.
Our informative 20th and 25th Anniversary Conferences brought dedicated researchers, world-renowned physicians, and hundreds of members together to learn and discuss the many aspects of endo. You can be part of it, too, when you order an anniversary CD or DVD. You'll also receive a newsletter about the conference. Please see order form. Some DVDs have more than one segment and ergotamine.
Bladder cancer transitional cell carcinoma of the bladder ; breast cancer carcinoma of the breast ; breast cancer invasive ductal carcinoma of the breast ; breast cancer lobular carcinoma of the breast ; non-hodgkin's lymphoma ovarian cancer adenocarcinoma of the ovary ; small cell lung cancer carcinoma of the lung ; stomach cancer adenocarcinoma of the stomach ; overview: epirubicin is an antineoplastic agent known as an anthracycline and epirubicin.
Peripheral effects of insulin in regulating the rate of glucose production. Experiments were performed in depancreatized dogs that were initially maintained at moderate hypergluycaemia 10mM ; with subbasal portal insulin infusion. During the experimental period, insulin was infused either peripherally or portally at 0.9 mU kg-1 min-1. In addition, peripheral infusions were also given at 0.45 mU. Kg-1 min-1. We concluded that when suprabasal insulin levels are provided to moderately hyperglycaemic depancreatized dog, the suppression of glucose production is more dependent on peripheral than portal insulin concentrations. This indirect effect of insulin may be mediated by limitation of the flow of precursors and energy sub-strates for gluconeogensis and or by suppressive effect of insulin on glucagons secretion. These results suggest that the absence of a portal-peripheral gradient in insulin-treated diabetic subjects may not be important for postprandial suppression of glucose production. 2 ; The glucagons-insulin ratio is an important regulator of glucose production by the liver during moderate exercise, whereas during intense exercise the catecholamines play a prominent role. Regulation of glucose uptake during exercise is very complex. In vivo, insulin can play an indirect role by inhibiting the FFA-glucose cycle and by maintaining nor-moglyaemia; both of these factors influence glucose uptake by the muscle . 3 ; Streptozocin-induced diabetes in rats decreases the number of cytochalasin B binding and by assessment of GLUT4 transporters. Normalization of glycaemia in the diabetic rats by a 2-day phlorizin treatment, which does not affect the insulinconcentration, normalizes glucose transporter number in the plasma membrane., We concluded that hyperglycaemia, per se, plays an important role in regulating glucose transporter number in the muscle. Syndrome of insulin resistance Flier J. S. Diabetes 1992; 41: 1207-19. The syndrome of insulin resistance are a group of clinically diverse disorders, and our understanding of their molecular pathogenesis has advanced in parallel with our understanding of the structure of the insulin receptor and the mechanism of insulin action. The most straightforward progress has related to defining the role of both anti-receptor antibodies and mutations in the insulin receptor gene in causing these disorders. Despite this progress, the cause of severe target cell resistance in patients without defects in the receptor locus remains unknown and we are limited in our ability to relate specific molecular defects in insulin signalling to in vivo phenotypes, such as those and erlotinib.
Ec epirubicin cyclophosphamide
26. Doroshow JH. Anthracyclines and anthracenediones. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1996: 409-434. 27. Platel D, Pouna P, Bonoron-Adele S, et al. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs. 1999; 10: 671-676. Robieux I, Spazzapan S, Fratino L, et al. Pharmacokinetics and safety of idarubicin continuous infusion CIV ; in elderly patients EP ; with aggressive lymphomas AL ; . Proc Annu Meet Soc Clin Oncol. 1998: A854. 29. Thomas X, Archimbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther. 1997; 39: 63-74. Review. 30. Wiseman LR, Spencer CM. Mitoxantrone: a review of its pharmacology and clinical efficacy in the management of hormoneresistant advanced prostate cancer. Drugs Aging. 1997; 10: 473-485. Review. 31. Small EJ. Prostate cancer. Curr Opin Oncol. 1997; 9: 277-286. Review. 32. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol. 1988; 6: 976-982. Praga C, Trave F, Petroccione A, et al. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. Boca Raton, Fla: CRC Press; 1991: 131-142. 34. Nicolella D, Grimaldi G, Colantuoni G, et al. Weekly low dose epirubicin in elderly cancer patients. Tumori. 1996; 82: 369-371. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997; 15: 987-993. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997; 54 suppl 4 ; : 22-29. Review. 37. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance MDR1 ; and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997; 89: 3323-3329. Lichtman SM, Egorin M, Rosner G. Clinical pharmacology of paclitaxel in relation to patient age: CALGB 9762. Proc Annu Meet Soc Clin Oncol. 1999; 18: A732. 39. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998; 16: 153-158. Taylor CW, Wang LM, List AF, et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 1997; 33: 1693-1698. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998; 16: 1811-1819. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995; 13: 26432655. Review. 43. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999; 10: 33-38. Taxotere [package insert]. Parsippany, NJ: Aventis Pharmaceuticals Products Inc; 2000. 45. Burris HA. Optimal use of docetaxel Taxotere ; : maximizing its potential. Anticancer Drugs. 1996; 7 suppl 2 ; : 25-28. Review. 46. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998; 16: 187-196. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 2164-2168. Lyss AP. Enzymes and random synthetics. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, Md: Williams & Wilkins; 1992: 398-412. 49. Reed E, Dabholkar M, Chabner BA. Platinum analogues. In.
Epirubicin more for_patients
Epirubicin treatment
Androgel substitute, t-cell receptor rearrangement, visual agnosia inability, apgar zero and uric acid normal. Amlodipine tinnitus, left brain or right brain test, whipple procedure webmd and essential tremor of the face or wisdom tooth sore throat.
Epirubicin drug mechanism
Epirubciin, epiirubicin, epir8bicin, epirybicin, rpirubicin, epirrubicin, ep8rubicin, epiruvicin, epiruibcin, epriubicin, epirublcin, eirubicin, epkrubicin, epirubiccin, epirubcin, epirbuicin, epirubucin, epirubicln, epjrubicin, epirubifin.
Epirubicin hcl
Epirubicin taxotere, epirubicin dogs, epirubicin sicor, adriamycin epirubicin and epirubicin msds. Doxorubicin vs epirubicin, ec epirubicin cyclophosphamide, epirubicin more for_patients and epirubicin treatment or epirubicin drug mechanism.
|
